January 28, 2015

Ligand to Present at BIO CEO and RBC Capital Markets Global Healthcare Conferences in February

SAN DIEGO-- **Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)** announced today that company executives will be presenting at the following conferences:

- BIO CEO & Investor Conference in New York. John Higgins, President and Chief Executive Officer will present on Monday, February 9, 2015 at 8:00 a.m. Pacific (11:00 a.m. Eastern Time).
- RBC Capital Markets' 2015 Global Healthcare Conference in New York. Matt Foehr, Chief Operating Officer will present on Tuesday, February 24, 2015 at 1:05 p.m. Pacific (4:05 p.m. Eastern Time).

A live webcast of the presentations will be available on the Company's website www.ligand.com. A replay of the presentations will be archived on the site for 30 days.

About Ligand Pharmaceuticals

Ligand is a biopharmaceutical company with a business model that is based upon the concept of developing or acquiring royalty revenue generating assets and coupling them to a lean corporate cost structure. Ligand's goal is to produce a bottom line that supports a sustainably profitable business. By diversifying the portfolio of assets across numerous technology types, therapeutic areas, drug targets and industry partners, we offer investors an opportunity to invest in the increasingly complicated and unpredictable pharmaceutical industry. In comparison to its peers, we believe Ligand has assembled one of the largest and most diversified asset portfolios in the industry with the potential to generate revenue in the future. These therapies seek to address the unmet medical needs of patients for a broad spectrum of diseases including diabetes, hepatitis, muscle wasting, Alzheimer's disease, dyslipidemia, anemia, asthma and osteoporosis. Ligand's Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. Ligand has established multiple alliances with the world's leading pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals (a subsidiary of Amgen Inc.), Merck, Pfizer, Baxter International, Lundbeck Inc., Eli Lilly & Co. and Spectrum Pharmaceuticals. Please visit www.captisol.com for more information on Captisol and www.ligand.com for more information on Ligand.

Follow Ligand on Twitter @Ligand_LGND.

Ligand Pharmaceuticals Incorporated
John Higgins, President and CEO
(858) 550-7500
investors@ligand.com

@Ligand_LGND
or
LHA
Bruce Voss
(310) 691-7100
bvoss@lhai.com
@LHA_IR_PR

Source: Ligand Pharmaceuticals Incorporated